A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines DNA.HTI and MVA.HTI in Early Treated HIV-1 Positive Individuals

Trial Profile

A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines DNA.HTI and MVA.HTI in Early Treated HIV-1 Positive Individuals

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2018

At a glance

  • Drugs HTI immunogen (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms AELIX-002
  • Sponsors Aelix Therapeutics
  • Most Recent Events

    • 20 Mar 2018 Planned number of patients changed from 15 to 45.
    • 20 Mar 2018 Planned End Date changed from 1 May 2018 to 31 Jan 2020.
    • 20 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 30 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top